Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
NCT00174291
Last updated date
ABOUT THIS STUDY
- To evaluate the effect of increasing the growth hormone dose on the statural response
- To assess the value of early treatment during the course of arthritic disease by
comparing the height acquired in the medium term by children in the two groups: treated
from the start, or 1 year to 15 months after the diagnosis of CJA, or treated for 4
years after the diagnosis
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Endocrine System Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
4-14 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- This study will be proposed to all patients previously included in study CTN 97-8129-016
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Discontinuation of corticosteroid therapy for more than a year during study CTN
97-8129-016
- Patients withdrawing from the study prematurely
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Endocrine System DiseasesGrowth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215
- Annemasse Cedex,
- Besancon,
- Bordeaux,
- Bordeaux,
- Bron Cedex,
- Dijon,
- Grenoble Cedex,
- Lorient,
- Lyon Cedex 05,
- Marseille,
- Montpellier,
- Paris,
- Paris,
- Paris,
- Paris,
- PRINGY Cedex,
- Toulouse Cedex,
- Vandoeuvre Les Nancy Cedex,
ALL GENDERS
11 Years+
years
MULTIPLE SITES
Endocrine System DiseasesPrevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
NCT00174291
- Paris,
ALL GENDERS
4 Years+
years
MULTIPLE SITES
Endocrine System DiseasesTreatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
NCT00174187
- Paris,
- Paris,
ALL GENDERS
11 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy | |||
| Official Title ICMJE | Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years | |||
| Brief Summary |
| |||
| Detailed Description | This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns. | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Endocrine System Diseases | |||
| Intervention ICMJE | Drug: Somatropin
Liquid, daily to final height Maximum Dosage: 50 µg/kg/day | |||
| Study Arms ICMJE | Experimental: Somatropin
Intervention: Drug: Somatropin | |||
| Publications * | David H, Aupiais C, Louveau B, Quartier P, Jacqz-Aigrain E, Carel JC, Simon D. Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4578-4587. doi: 10.1210/jc.2017-01455. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Terminated | |||
| Actual Enrollment ICMJE | 21 | |||
| Original Enrollment ICMJE | 30 | |||
| Actual Study Completion Date ICMJE | October 2011 | |||
| Actual Primary Completion Date | October 2011 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 4 Years to 14 Years (Child) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | France | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00174291 | |||
| Other Study ID Numbers ICMJE | 307-MET-9002-052 A6281024 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | October 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||